Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Expects To Launch Megestrol Suspension In August After Appellate Win

Executive Summary

Par Pharmaceutical expects to launch generic megestrol oral suspension in August, following a federal appellate court decision upholding its patent challenge to Bristol-Myers Squibb's Megace.

You may also be interested in...



Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix

A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform

Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix

A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform

Bristol Megace

Patent infringement complaint against Par Pharmaceutical regarding megestrol oral formulation dismissed Dec. 14 by the New York Southern District Court. Par's counterclaims for patent invalidity, unfair competition and interference remain. Par received a tentative approval in October and anticipates marketing no later than February 2002

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel